CUE
Cue Biopharma
27.70$
+23.9%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | -9.9% | +161.0% | -26.4% | +11.9% | +185.1% | -6.7% | +6.6% | -14.2% | +19.4% | -34.5% | -32.5% | +226.7% | +76.4% | -12.6% | +244.7% | -87.9% | -97.4% | +161.5% | +122.1% | +23.8% | +639.0% | +52.0% | -13.3% | -5.7% | +54.8% | +25.5% | -52.8% | -73.3% | +601.7% | -27.3% | +921.0% | -74.1% | +38.5% | – | |
| – | – | – | – | +17.1% | +125.4% | -35.5% | -7.0% | +90.5% | -33.8% | +22.4% | -17.8% | -22.8% | +31.4% | +42.2% | -18.0% | -7.4% | +6.5% | +22.6% | -10.7% | +28.8% | +1.9% | -12.3% | -4.9% | -21.1% | +6.3% | -89.1% | -3.6% | +958.3% | +50.3% | -93.7% | +1,022.5% | – | – | – | – | -21.0% | +3,958.2% | -97.6% | -53.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +639.0% | -597.4% | – | – | +54.8% | +25.5% | -52.8% | -73.3% | +601.7% | -29.9% | +960.0% | -74.1% | +37.9% | – | |
| – | +47.5% | +19.2% | +38.8% | +17.1% | +125.4% | -35.5% | -7.0% | +90.5% | -33.8% | +22.4% | -17.8% | -22.8% | +31.4% | +42.2% | -18.0% | -7.4% | +6.5% | +22.6% | -10.7% | +28.8% | +1.9% | -12.3% | -4.9% | -21.1% | +49.7% | -17.1% | +13.4% | -7.3% | +10.3% | -6.3% | -6.6% | -1.6% | -23.4% | +19.0% | -7.5% | -40.8% | +252.8% | -58.3% | +610.6% | – | |
| – | +24.5% | +14.4% | +12.0% | +3.4% | +37.8% | +20.0% | +30.9% | +29.8% | +54.5% | -23.0% | -0.7% | -18.8% | +2.9% | +30.7% | -2.5% | -17.0% | +5.2% | +25.4% | +0.7% | -3.8% | +13.0% | +11.6% | -27.4% | -5.4% | +5.2% | +18.6% | +1.7% | -14.2% | +26.4% | -9.2% | -16.3% | -18.2% | +40.3% | +3.8% | -11.9% | +34.1% | -30.0% | +20.3% | +1,021.5% | – | |
| – | +40.4% | +17.9% | +31.7% | +14.0% | +107.5% | -27.9% | +1.6% | +72.8% | -14.5% | +4.4% | -12.8% | -21.5% | -61.6% | +28.7% | -2.3% | -14.9% | +3.9% | +23.5% | +0.6% | -3.6% | +12.6% | +11.0% | -31.7% | +0.1% | +97.5% | +94.7% | +9.8% | -69.5% | -52.3% | +564.1% | -9.3% | -6.8% | -7.8% | +13.5% | -8.9% | -17.0% | +107.9% | -44.7% | +765.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -373.9% | – | – | |
| – | – | – | – | – | – | – | – | -40.0% | -100.0% | – | -15.8% | +3.1% | – | – | -3.8% | -8.0% | -83.0% | +232.1% | +84.6% | +4.2% | -96.0% | +2,400.0% | +724.0% | -39.8% | +189.4% | +3.1% | -37.3% | +23.3% | +77.3% | -52.5% | -10.8% | -12.6% | -18.6% | -16.3% | -64.8% | +66.7% | -32.0% | -92.2% | +25.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -243.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -348.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -124.0% | – | -40,700.0% | – | -119.9% | – | +0.0% | – | – | +24,650.0% | -96.6% | +594.1% | -164.4% | – | – | +469.7% | +24.1% | +15.3% | -0.2% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -426.7% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -227.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.